衰弱对ADVANCE试验中强化降糖与降压治疗疗效及安全性的影响
基于ADVANCE试验11,140例2型糖尿病患者,回顾性构建衰弱指数(FI>0.21定义衰弱),分析衰弱与强化降糖及降压治疗疗效和安全性的关系。结果显示衰弱是主要及次要结局的独立预测因素,衰弱者强化降糖对大血管和微血管复合事件的获益减弱,严重低血糖发生率更高。
要点
- 衰弱(FI>0.21)是2型糖尿病患者不良结局的独立预测因素。
- 衰弱者强化降糖对大血管和微血管复合事件的获益减弱(HR 1.03 vs 0.84,P=0.02)。
- 衰弱者严重低血糖发生率更高(8.39 vs 4.80/1000人年,P<0.001)。
核心结论
- 回顾性构建的衰弱指数可识别不良结局高风险患者。
- 衰弱者从强化降糖和降压治疗中的获益有所减弱。
研究设计与样本
- 基于ADVANCE试验11,140例2型糖尿病参与者的回顾性分析。
- 采用Cox比例风险模型评估按衰弱状态(FI>0.21)分层的强化降糖和降压治疗疗效与安全性。
- 参与者平均年龄65.8岁,女性占42.5%,衰弱者占25.7%。
主要发现
- 衰弱是全因死亡、心血管死亡、严重低血糖等所有主要和次要结局的独立预测因素。
- 衰弱者强化降糖对主要大血管和微血管复合事件的HR为1.03(95%CI 0.90-1.19),非衰弱者为0.84(95%CI 0.74-0.94),P=0.02。
- 降压干预在衰弱者中呈现类似获益减弱的趋势。
- 衰弱者严重低血糖发生率为8.39/1000人年(95%CI 6.15-10.63),非衰弱者为4.80/1000人年(95%CI 3.84-5.76),P<0.001。
- 因低血压/头晕停用降压治疗在衰弱与非衰弱组间无显著差异。
临床怎么用
- 对2型糖尿病患者评估衰弱状态有助于识别强化治疗获益可能减弱且低血糖风险更高的人群。
- 衰弱患者强化降糖需权衡获益与严重低血糖风险。
局限性
- 衰弱指数为在试验人群中回顾性估算,非前瞻性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop a frailty index (FI) and explore the relationship of frailty to subsequent adverse outcomes on the effectiveness and safety of more intensive control of both blood glucose and blood pressure (BP), among participants with type 2 diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. RESEARCH DESIGN AND METHODS: Cox proportional hazard models were used to estimate the effectiveness and safety of intensive glucose control and BP intervention according to frailty (defined as FI >0.21) status. The primary outcomes were macro- and microvascular events. The secondary outcomes were all-cause mortality, cardiovascular mortality, severe hypoglycemia, and discontinuation of BP treatment due to hypotension/dizziness. RESULTS: There were 11,140 participants (mean age, 65.8 years; 42.5% women, 25.7% frail). Frailty was an independent predictor of all primary outcomes and secondary outcomes. The effect of intensive glucose treatment on primary outcomes showed some evidence of attenuation in the frail: hazard ratios for combined major macro- and microvascular events 1.03 (95% CI 0.90-1.19) in the frail versus 0.84 (95% CI 0.74-0.94) in the nonfrail (P = 0.02). A similar trend was observed with BP intervention. Severe hypoglycemia rates (per 1,000 person-years) were higher in the frail: 8.39 (6.15-10.63) vs. 4.80 (3.84-5.76) in nonfrail (P < 0.001). There was no significant difference in discontinuation of BP treatment between frailty groups. CONCLUSIONS: It was possible to retrospectively estimate frailty in a trial population, and this FI identified those at higher risk of poor outcomes. Participants with frailty had some attenuation of benefit from intensive glucose-lowering and BP-lowering treatments.
引用
- Nguyen TN, Harris K, Woodward M, et al. The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure-Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial. Diabetes Care. 2021. PMID: 34035077. doi:10.2337/dc20-2664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。